Latest Conference Articles

Early-stage study results from the multi-center MUST-ARDS trial show the ex-vivo adult progenitor cell-expanding therapy is capable of improving 28-day mortality, care burden, and overall safety in patients with ARDS.

Mental health disorders are highly prevalent in certain patients with COPD—and their effect can limit lung function therapy benefit.

Early research found that e-cigarette use affects the immune system response to the flu virus and the effects are different for female and male users.

A multivariate cohort showed opioids in situation of critical care may not drive rates of continued use after 1 year.

The intracellular tyrosine kinases inhibitor has a similar benefit for patients with the rare, heterogenous associated form of ILD as it does for patients with IPF.

Among patients in SINUS-24 and SINUS-52 with chronic rhinosinusitis with nasal polyps and comorbid asthma, dupilumab significantly improved function and patient-reported outcomes.

Does it matter whether federal and state regulations allow for a significant user population?

How new GRIPHON data showed further definitive long-term outcomes for patients with pulmonary hypertension.

Why are diagnoses still significantly underwhelming for a chronic condition on the rise?

High-risk LIVE scores for patients with COPD were associated with higher all-cause mortality and higher rates of referral to palliative care.

New Sunovion data at ATS 2019 shows expected trends of comorbidity effect on patients, and surprising results of care between men and women.

In an open-label trial among adults with mild asthma, budesonide-formoterol treatment was superior to albuterol for the prevention of asthma exacerbations.

Investigators were seeking an alternative therapy for persistent asthma patients reporting insufficient benefit from mometasone, despite it being the guideline standard.

Investigators found that female sex, older age, and certain comorbidities were associated with an increased risk of uveitis.

Using a national medical claims database, investigators found the incidence and prevalence of uveitis in the US.

Results from the 3-year European Iluvien Registry Safety Study that examined outcomes of the fluocinolone acetonide implant compared to those of the pivotal FAME trials.

Investigators calculated perilesional sensitivity and responding sensitivity for eyes in a geographic atrophy clinical trial and compared these to mean retinal sensitivity.

Chang and colleagues are developing an outcome for geographic atrophy trials that measures vision loss rather than structural changes.

A study presented at ARVO 2019 examines the long-term safety of BAK-free latanoprost for treatment of open-angle glaucoma or ocular hypertension

A recent study, presented at ARVO 2019, found that ophthalmologists have 77% greater odds of experiencing professional fulfillment, but ophthalmology residents are 3 times more likely to express an intent to leave the field than other surgical residents.

A study from ARVO 2019 found that, while optometrists are likely to prescribe them, many are still split over the impact of blue light-blocking devices

A tear-based biomarker for Parkinson disease would allow providers to diagnose the condition sooner and create a measurement tool for new drug development.

Investigators found significant differences in ocular flow velocity between patients with preeclampsia and without who had recently given birth.

Identifying a potential biomarker is an extended process, one which benefits from collaboration between researchers and clinicians of many specialties.

The placenta plays a major role in preeclampsia but is difficult to access. Investigators have turned to the eye, the choroid in particular, looking for clues about this serious condition.

Pinakin Davey, DO, PhD, discusses the findings of his study comparing reliability of testing methodologies for visual acuity and contrast sensitivity at ARVO 2019.

People experiencing homelessness were more likely to follow-up on referrals from an ophthalmology clinic if they had finished high school or had a primary care provider.

The ZEBRA study found that ziv-aflibercept was non-inferior to aflibercept and ranibizumab, and was more cost-effective.

Mia Woodward, MD, discusses the findings of her study which explored the possible over prescription and use of opioids post-corneal surgery.

The field has a growing demand of care, and dropping rate of new specialists. The solution can start at medical schools.